ArticleJournal of asthma and allergy2026
Racial and Socioeconomic Differences in Real-World Use of Biologic Therapy for Asthma.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Determine if there is a difference in race, socioeconomic factors and baseline asthma severity at the time of biologic initiation and whether those characteristics are associated with response to therapy within 18 months of initiation. Additionally, evaluate racial differences in clinic engagement, healthcare utilization, and biologic adherence. Patients and Methods: Retrospective review of patients initiating biologic therapy for moderate-severe asthma from January 1, 2019-June 30, 2022. Multiple linear regression analyses were performed to examine whether race and socioeconomic status were associated with race-neutral percent predicted forced expiratory volume in one second (ppFEV1) prior to biologic prescription and within 18 months post biologic initiation. Differences in clinic engagement and healthcare utilization by race were assessed using Wilcoxon rank sum tests. Adherence was calculated using proportion of days covered (PDC). Results: Patients (N=215) were White (69%) or Black or African American (27%). Most had commercial (54%) or Medicare (22%) insurance. At the time of biologic initiation, Black or African American/Other patients were estimated to have a 6.9% lower ppFEV1 than White patients ( Conclusion: Although not statistically significant, our findings suggest a possible trend where Black or African American/Other patients had lower ppFEV1 at the time of biologic initiation, indicating an opportunity for earlier interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.